Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), break down other data in metastatic uveal melanoma from the 2025 ESMO Congress.
Prof. Andrea Forschner (DO)
Advertisement
Articles by Prof. Andrea Forschner (DO)
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), discuss other ways percutaneous hepatic perfusion could be integrated into metastatic uveal melanoma management.
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), discuss the potential clinical implications of the CHOPIN trial in metastatic uveal melanoma.
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), break down data from the phase 2 CHOPIN trial evaluating percutaneous hepatic perfusion plus nivolumab and ipilimumab in metastatic uveal melanoma.
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), discuss the use of percutaneous hepatic perfusion in metastatic uveal melanoma.
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), highlight current treatment approaches in metastatic uveal melanoma.
Prof. Andrea Forschner (DO), and Dr. Shaheer Ahmad Khan (MD), explore potential future research directions in metastatic uveal melanoma.
Advertisement
Latest Updated Articles
Other Strategies Incorporating Percutaneous Hepatic Perfusion in Metastatic Uveal MelanomaPublished: December 23rd 2025 | Updated:
- Exploring Percutaneous Hepatic Perfusion in Metastatic Uveal Melanoma
Published: December 9th 2025 | Updated:
- Highlighting Other Uveal Melanoma Data From ESMO 2025 and Beyond
Published: December 23rd 2025 | Updated:
- CHOPIN Trial: Percutaneous Hepatic Perfusion Plus Nivolumab/Ipilimumab in Metastatic Uveal Melanoma
Published: December 16th 2025 | Updated:
- Future Research Directions in Metastatic Uveal Melanoma
Published: January 8th 2025 | Updated:
- Exploring Potential Implications of CHOPIN Trial Data in Metastatic Uveal Melanoma
Published: December 16th 2025 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5